Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C37H34N6O2 |
| Molecular Weight | 594.7049 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N(CC1=CC=CC=C1)C(=O)CN2C3=CC=CC=C3N4C(=NN=C4C5=CC=CC=C5)[C@H](CC6=CNC7=C6C=CC=C7)C2=O
InChI
InChIKey=UBNMGTSDHSQBEL-PMERELPUSA-N
InChI=1S/C37H34N6O2/c1-25(2)41(23-26-13-5-3-6-14-26)34(44)24-42-32-19-11-12-20-33(32)43-35(27-15-7-4-8-16-27)39-40-36(43)30(37(42)45)21-28-22-38-31-18-10-9-17-29(28)31/h3-20,22,25,30,38H,21,23-24H2,1-2H3/t30-/m0/s1
| Molecular Formula | C37H34N6O2 |
| Molecular Weight | 594.7049 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CE-326597 is a potent and selective agonist of type 1 cholecystokinin receptor, developed by Pfizer Inc for the treatment of obesity. The physical properties of CE-326597 provided the desired low systemic exposure which was driven by poor absorption of the drug into the intestinal wall. Unfortunately, CE-326597 demonstrated insufficient efficacy for the treatment of either diabetes or obesity after 12 weeks of dosing in Phase 2 clinical trial and was discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. | 2015-12-24 |
|
| Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity. | 2010-11-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00542009
100 mg QD
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:00:19 GMT 2025
by
admin
on
Mon Mar 31 23:00:19 GMT 2025
|
| Record UNII |
1FGZ6L9SF2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
52949124
Created by
admin on Mon Mar 31 23:00:19 GMT 2025 , Edited by admin on Mon Mar 31 23:00:19 GMT 2025
|
PRIMARY | |||
|
870615-40-0
Created by
admin on Mon Mar 31 23:00:19 GMT 2025 , Edited by admin on Mon Mar 31 23:00:19 GMT 2025
|
PRIMARY | |||
|
DB12694
Created by
admin on Mon Mar 31 23:00:19 GMT 2025 , Edited by admin on Mon Mar 31 23:00:19 GMT 2025
|
PRIMARY | |||
|
1FGZ6L9SF2
Created by
admin on Mon Mar 31 23:00:19 GMT 2025 , Edited by admin on Mon Mar 31 23:00:19 GMT 2025
|
PRIMARY | |||
|
300000041481
Created by
admin on Mon Mar 31 23:00:19 GMT 2025 , Edited by admin on Mon Mar 31 23:00:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|